top of page

Long-term effectiveness of gastric bypass in treating type 2 diabetes and obesity

Roux-en-Y gastric bypass kept type 2 diabetes in remission for up to 15 years and most of the weight off for up to 20 years in one of the largest long-term studies of patients undergoing the procedure. The findings were presented in the study, ‘Long Term (> 15 Year) Outcomes Following Roux-en-Y Gastric Bypass’, at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting.

“With the availability of medical and endoscopic therapies, the demonstration of long-term effectiveness of gastric bypass that exceeds that of these alternatives is critical to providing the right intervention for the right patient at the right time,” said study author, Dr Anthony T Petrick, Director, Division of Bariatric and Foregut Surgery, Geisinger Health System.

For the study, Petrick and his colleagues from Geisinger Medical Center in Danville, PA, analysed diabetes remission rates and weight-loss outcomes of 2,045 patients who had a gastric bypass at their centre between 2001 and 2008 and followed them for up to 20 years. Patients, on average, were 46 years old with a body mass index (BMI) of 47.9, prior to surgery.

Of the 677 patients with pre-operative diabetes, remission rates were 54% at the three-year mark but dropped to 38% after 15 years. Only about 10% of patients with insulin-dependent diabetes had remission in the same timeframe and the rate of persistent diabetes was higher in patients who had insulin-treated diabetes before surgery. 

Peak weight loss of 31.8% was achieved after 18 months and stabilised at 23% after ten years and up to the 20-year mark. The overall 15-year mortality rate was 13.3%, which was 37.4% among patients with diabetes and older than 60. No deaths were related to the surgical procedure itself.

“The study is an important contribution to the current understanding of long-term outcomes of gastric bypass because of the extremely high follow-up rates,” said Dr Marina Kurian, ASMBS President, who was not involved in the study.


bottom of page